Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 89

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 89
---
., Ph.D. |     |                         | — |     |                   | — |     |                        | 29,121 |     |                   |   910,975 |
| Tsveta Milanova           |     |                         | — |     |                   | — |     |                        | 13,923 |     |                   |   311,869 |

| (1) | The value realized when the stock options were exercised represents the excess of the fair market value of the shares at the time of exercise over the exercise price of the stock options. |

| (2) | The value realized when the stock awards vested represents the number of shares underlying the units vested multiplied by market value of the shares on the vesting date. |

Employment, Severance and Change in Control Arrangements Employment Offer Letters and Employment Agreements We have entered into employment offer letters or employment agreements with each of our NEOs pursuant to which such NEO is employed “at will,” meaning we or each NEO may terminate the employment arrangement at any time. Such offer letters establish the NEO’s title, initial compensation arrangements, and eligibility for benefits made available to employees generally. In connection with his appointment as chief executive officer, we entered into an employment agreement with Mr. Goff, effective August 8, 2022, providing for the terms of his employment, including (i) an annual base salary of $775,000; (ii) an annual target bonus of at least 70% of his base salary, to be pro-ratedwith respect to 2022; (iii) a one-time grant ofan option to purchase 561,083 shares of common stock at an exercise price of $29.38 per share, the closing price on the date of grant, which vested as to 25% of the underlying shares on August 8, 2023 and vests as to the remaining shares on a monthly basis thereafter; (iv) a one-time grantof 68,073 RSUs, each unit representing a contingent right to receive one share of common stock, which vest in equal annual installments on the first, second and third anniversaries of the date of grant; (v) a one-time grantof 170,183 PSUs, each unit representing a contingent right to receive one share of common stock, which vest as to the underlying shares of common stock upon the achievement of specified research, clinical and regulatory milestones, which are more fully described under “2022 PSU Awards to Chief Executive Officer” above; (vi